Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Discontinuation of infliximab therapy in patients with Crohn's disease in sustained complete remission (the STOP IT study): protocol for a double-blind, randomised, placebo-controlled, multicentre trial

Research output: Contribution to journalJournal articleResearchpeer-review

  1. The six-gene expression signature in whole sampled sputum provides clinically feasible inflammatory phenotyping of asthma

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Fast-track pneumonia pathway focusing on early progressive mobilisation: a clinical feasibility study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Pulmonary exacerbations in patients with primary ciliary dyskinesia: an expert consensus definition for use in clinical trials

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Sexual transmission of Hepatitis C Virus infection in a heterosexual population: A systematic review

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Therapeutic thresholds and mechanisms for primary non-response to infliximab in inflammatory bowel disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Personalized medicine in rheumatoid arthritis: How immunogenicity impacts use of TNF inhibitors

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Pattern recognition receptor polymorphisms in early periodontitis

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Lewis and AB0 blood group-phenotypes in periodontitis, cardiovascular disease, obesity and stroke

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Sine Schnoor Buhl
  • Casper Steenholdt
  • Jørn Brynskov
  • Ole Østergaard Thomsen
  • Klaus Bendtzen
  • Mark Andrew Ainsworth
View graph of relations

INTRODUCTION: Infliximab (IFX), a monoclonal chimeric antibody against tumour necrosis factor (TNF) α, is effective for induction and maintenance of remission in moderate to severe Crohn's disease. Discontinuation of IFX maintenance therapy in patients in remission should be considered in order to reduce the potential long-term side effects and lower costs.

METHODS AND ANALYSIS: This is a prospective, double-blind, randomised, placebo-controlled, multicentre study of patients with luminal Crohn's disease who have been treated with IFX for at least 1 year and are in sustained complete clinical, biochemical and endoscopic remission (ie, Crohn's Disease Activity Index (CDAI) score <150, complete mucosal healing and biochemical markers of inflammation within the normal range). These patients are randomised to receive placebo infusions or continue IFX maintenance therapy. The primary end point is the proportion of patients in maintained remission after 48 weeks (def. CDAI <150).

ETHICS AND DISSEMINATION: It is estimated that the knowledge gained about how to optimally handle patients with Crohn's disease in complete long-term sustained remission on IFX is proportionate to the risks and inconveniences related to participation in this study. Prolonged exposure to IFX may cause severe side effects and increased risk of malignancies. Conversely, IFX discontinuation should not unnecessarily create a high risk of relapse. Thus, empirical evidence is needed concerning the safety of discontinuing IFX once a patient exhibits sustained remission. Study results will be published in an English language scientific medical journal. The study is approved by the Danish Medicines Agency (EudraCT-number: 2012-002702-51) and the Regional Ethics Committee of Region Hovedstaden Denmark (Approval-number: H-4-2012-099). The project is reported to the Danish Data Protection Agency (ID-number: 2007-58-0015/HEH.750.89-27), registered at Clinicaltrials.gov, and monitored by independent GCP units for the University of Copenhagen, Odense and Aarhus. The current approved protocol is V.3.2, dated 1 June 2014.

TRIAL REGISTRATION NUMBER: http://clinicaltrials.gov/show/NCT01817426.

Original languageEnglish
JournalB M J Open
Volume4
Issue number12
Pages (from-to)e005887
ISSN2044-6055
DOIs
Publication statusPublished - 2014

ID: 44833333